William Blair started coverage on shares of Cambrex (NYSE:CBM) in a research note issued to investors on Tuesday. The firm set an “outperform” rating on the biotechnology company’s stock.

CBM has been the topic of a number of other reports. Zacks Investment Research upgraded Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday. Craig Hallum restated a “buy” rating and issued a $60.00 price objective (down from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $62.33.

Shares of Cambrex (CBM) opened at $51.65 on Tuesday. The company has a market capitalization of $1,692.96, a price-to-earnings ratio of 17.22, a PEG ratio of 1.25 and a beta of 2.27. Cambrex has a 52 week low of $42.55 and a 52 week high of $62.95.

Cambrex (NYSE:CBM) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.08. Cambrex had a return on equity of 23.42% and a net margin of 18.79%. The business had revenue of $112.60 million for the quarter, compared to analysts’ expectations of $108.44 million. During the same period in the previous year, the business posted $0.47 EPS. The firm’s quarterly revenue was up 13.4% compared to the same quarter last year. equities analysts expect that Cambrex will post 2.97 EPS for the current year.

Institutional investors have recently made changes to their positions in the stock. YorkBridge Wealth Partners LLC raised its stake in Cambrex by 5.2% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 97 shares during the period. Riverhead Capital Management LLC raised its stake in Cambrex by 90.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after acquiring an additional 1,264 shares during the period. Advisor Group Inc. raised its stake in Cambrex by 29.8% in the 2nd quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock valued at $160,000 after acquiring an additional 615 shares during the period. Visionary Asset Management Inc. bought a new stake in Cambrex in the 3rd quarter valued at about $201,000. Finally, Trexquant Investment LP bought a new stake in Cambrex in the 3rd quarter valued at about $209,000.

WARNING: “Cambrex (CBM) Now Covered by William Blair” was originally published by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/16/cambrex-cbm-now-covered-by-william-blair.html.

Cambrex Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.